Skip to main content

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Project description

Decreasing resistance to an important treatment for tuberculosis

Infectious diseases are caused by bacteria, viruses, fungi, and parasites. There are vaccines to prevent infection or medicines to kill the organisms but an increasing number of organisms are becoming resistant to treatments. Tuberculosis (TB) is caused by Mycobacterium tuberculosis. In many cases, these bacteria are resistant to multiple drugs, some with lethal results. The EU-funded TRIC-TB project is exploring a promising way to boost the effectiveness of treatment for multidrug-resistant TB. With a focus on restoring sensitivity to an existing line of treatment, scientists hope to improve patient outcomes regardless of initial resistance status at the time of infection.

Coordinator

BIOVERSYS AG
Net EU contribution
€ 6 813 875,00
Address
Hochbergerstrasse 60 C Technologiepark Basel
4057 Basel
Switzerland

See on map

Region
Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 29 375,00

Participants (2)

Third-party

Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.

BioVersys SAS
France
Net EU contribution
€ 112 500,00
Address
Institut Pasteur De Lille U1177, 1 Rue Du Professeur Calmette
59000 Lille

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Hauts-de-France Nord-Pas de Calais Nord
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL
Spain
Net EU contribution
€ 0,00
Address
C/ Severo Ochoa Numero 2 Parque Tecnologico De Mad
28760 Tres Cantos Madrid

See on map

Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 1 417 500,00